On-Demand Webinar
Switching to enzymatically produced DNA formats and optimized non-viral delivery vehicles can address two of the most persistent bottlenecks in gene therapy development: DNA toxicity and suboptimal delivery efficiency. This session presents comparative data from two complementary platforms, examining how advanced DNA payload formats and lipid and polymer-based delivery systems can together reduce immune sensing, improve therapeutic dosing, and enhance T cell editing outcomes.
You will see head-to-head data comparing dbDNA and mbDNA against plasmid DNA across multiple delivery contexts, including systemic and local in vivo delivery and HDR-based T cell editing, alongside performance data for a preassembled lipid-based nanoparticle platform for RNA and DNA delivery into T cells.
watch this webinar to understand how combining advances in payload design and delivery platform selection can reduce reliance on viral vectors and support more efficient, scalable non-viral gene therapy programs.
has context menu
What You Will Learn:
- Review in vivo data demonstrating superior expression magnitude and durability of dbDNA versus plasmid DNA across multiple organs after systemic delivery, and in muscle tissue via local administration using non-viral delivery solutions
- Examine T cell editing data showing improved HDR efficiency and cell viability using mbDNA and dbDNA compared to plasmid DNA, with implications for repeat dosing and immune evasion
- Explore the performance of a pre-formed vesicles (PFVs) solution, LipidBrick® Cell Ready, a lipid-based nanoparticle platform for stable editing and transient expression in T cells
- Gain practical guidance on selecting DNA payload formats and delivery formulations based on application requirements, without the need to develop these capabilities in-house
